Russell Investments Group Ltd. Sells 76,565 Shares of AbbVie Inc. $ABBV

Posted by George Bondi on Nov 13th, 2026

Russell Investments Group Ltd. decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 4.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,544,550 shares of the company’s stock after selling 76,565 shares during the quarter. Russell Investments Group Ltd.’s holdings in AbbVie were worth $404,308,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. Burk Holdings LLC acquired a new position in shares of AbbVie during the second quarter valued at $30,000. Marquette Asset Management LLC increased its holdings in shares of AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after acquiring an additional 48 shares during the period. Principia Wealth Advisory LLC increased its holdings in shares of AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after acquiring an additional 44 shares during the period. IMG Wealth Management Inc. lifted its position in AbbVie by 3,060.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock valued at $40,000 after purchasing an additional 153 shares during the last quarter. Finally, Tacita Capital Inc bought a new stake in AbbVie in the 2nd quarter valued at about $42,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the sale, the executive vice president owned 83,171 shares of the company’s stock, valued at $24,419,005.60. The trade was a 32.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ABBV shares. Sanford C. Bernstein reissued a “market perform” rating and set a $275.00 target price on shares of AbbVie in a research note on Monday, November 2nd. Barclays raised their price target on shares of AbbVie from $300.00 to $325.00 and gave the company an “overweight” rating in a research note on Wednesday, October 21st. BNP Paribas Exane lifted their price target on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Rothschild & Co Redburn lifted their price target on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Finally, Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and boosted their price objective for the stock from $235.00 to $300.00 in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $297.46.

View Our Latest Research Report on ABBV

Trending Headlines about AbbVie

Investors following ABBV have been watching these headlines:

Positive Sentiment: AbbVie’s immunology sales rose 16.6% in the third quarter, with Skyrizi and Rinvoq growth more than offsetting Humira’s decline. The performance has supported higher 2026 sales expectations and strengthens the case that newer drugs can sustain growth. How Did AbbVie’s Immunology Franchise Fare in Q3?
Positive Sentiment: AbbVie recently raised its 2026 revenue guidance to about $67.8 billion and increased its dividend after reporting third-quarter revenue of $17.4 billion. These updates reinforce the company’s earnings and shareholder-return outlook. Can AbbVie Justify Its Valuation After Raised Guidance and Strong Results?
Negative Sentiment: Executive Vice President Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. Insider sales can weigh on sentiment, though the filing does not explain the reason for the transaction. SEC Form 4 filing

AbbVie Stock Down 0.1%

Shares of NYSE ABBV opened at $294.75 on Friday. The stock has a market cap of $521.01 billion, a P/E ratio of 50.73, a P/E/G ratio of 1.34 and a beta of 0.20. The firm’s 50-day simple moving average is $274.82 and its 200 day simple moving average is $240.55. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $302.93.

AbbVie (NYSE:ABBV – Get Free Report) last announced its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. The firm had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. AbbVie’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.86 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 13.98 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be paid a dividend of $1.82 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Friday, January 15th. AbbVie’s dividend payout ratio (DPR) is 119.10%.

About AbbVie

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.